Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for a Novel Glucagon-Like Peptide-1 Analogue, GZR18

Gan & Lee Pharmaceuticals Co., Ltd. announced that the US FDA has cleared the Investigational New Drug application for the company’s compound, GZR18, to improve the management of type 2 diabetes mellitus.